Pioneering novel immunotherapies
through AI-led TCR & antibody design
Powered by cutting-edge drug discovery AI & EXPERIMENTAL validation
PARTNERED WITH
OUR MISSION
Pioneer the combination of machine and human intelligence to develop the best immunotherapies for cancer patients in urgent need
3
TCR and Antibody specific LLMs fine-tuned/created
3
Pipeline programmes
6
In silico design to lead candidates in six months
HOW CAN WE HELP YOU?
Elevate your drug discovery outcomes.
We deliver safer, more precise drug candidates for your pipeline – faster.
How it works
Rapid design & engineering of new candidates and biobetters
Design, optimise and validate TCRs, Antibodies, Bispecifics and VHHs.
See how we engineered a TCR to 5 million fold improvement using our EMLy AI.
See how we supercharge stability and developability of a TCR asset.
Unlock the full potential of your research with EMLy Co-pilot & LLMs
Industry-first TCR and antibody-specific LLMs connected to EMLy co-pilot, empowering scientists with cutting-edge informatics & insights.
Discover how we identify novel targets and therapeutics through the Long term Cancer Survivor Program
Leverage our unmatched scale in deep sequencing, enhanced by EMLy AI error correction, to boost immune repertoire accuracy and align with our exclusive proprietary databases.
Discover how we identify our next target through the Long Term Survivor Programme.
